反応式
[F-].[Cs+].Br[C:4]1[N:9]=[C:8]2[N:10]([CH2:13][C:14]3[CH:15]=[C:16]4[C:21](=[CH:22][CH:23]=3)[N:20]=[CH:19][CH:18]=[CH:17]4)[N:11]=[N:12][C:7]2=[N:6][CH:5]=1.CC1(C)C(C)(C)OB([C:32]2[CH:33]=[N:34][N:35](C(OC(C)(C)C)=O)[CH:36]=2)O1.C(Cl)Cl>C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2].O.COCCOC>[NH:34]1[CH:33]=[C:32]([C:4]2[N:9]=[C:8]3[N:10]([CH2:13][C:14]4[CH:15]=[C:16]5[C:21](=[CH:22][CH:23]=4)[N:20]=[CH:19][CH:18]=[CH:17]5)[N:11]=[N:12][C:7]3=[N:6][CH:5]=2)[CH:36]=[N:35]1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 3
反応条件
- 温度
- 80 °C
実験手順
A mixture of DME (3.0 mL) and 1 M aqueous CsF (0.88 mL) was degassed by bubbling in Argon for 10 minutes. The mixture was transferred via syringe to a vial containing 6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline (100 mg, 0.29 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (95 mg, 0.32 mmol) and Pd(dppf)2Cl2.CH2Cl2 (6.1 mg, 0.01 mmol). The vial was capped and heated to 80° C. for 16 hours. Water (5 mL) was added to the crude reaction mixture and the resulting suspension was filtered. The precipitate was washed with water and air dried. The precipitate was purified by column chromatography using gradient elution with methanol and dichloromethane to afford 6-((6-(1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline (60 mg, 62%).
後処理
- customwas degassed
- customby bubbling in Argon for 10 minutes
- customThe mixture was transferred via syringe
- customThe vial was capped
- customreaction mixture
- filtrationthe resulting suspension was filtered
- washThe precipitate was washed with water and air
- customdried
- customThe precipitate was purified by column chromatography
- washelution with methanol and dichloromethane
出典と根拠
- ORDレコード
- ord-7f31b0d2072d4f86b3553365e5f36888
- 出典データセット
- uspto-grants-2010_06
- 特許番号
- US07732604B2
関連ノート
読み込み中…